IMMUNIC INC
IMUXNASDAQTrading Snapshot
- Day Range
- $15.01 β $15.50
- 52-Week Range
- $5.06 β $15.84
- Volume
- $3.25B
- Avg Volume
- $2.71B
- Shares Outstanding
- 13.6M
- Next Earnings
- Oct 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $15M
- Last Q Revenue
- $4M
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-5.42
- Dividend Yield
- β
Why Investors Own IMUX
- βHigh-growth profile β revenue up +52.8% YoY with expanding US Equity exposure.
- βHealthy economics β 32% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IMMUNIC INC
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORΞ³t, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.